Of note, Elovl1, which was enriched in the liver in the initial screening, proved to be a highly efficient target to combat primary tumour and peritoneal metastasis, supporting the relevance of our multi-dimensional approach in identifying promising targets with enhanced systemic fitness. Here, ELOVL1 is linked to neoplasm.